company background image
QBIO logo

Q BioMed OTCPK:QBIO Stock Report

Last Price

US$0.0001

Market Cap

US$14.5k

7D

0%

1Y

-83.3%

Updated

29 Nov, 2024

Data

Company Financials

QBIO Stock Overview

A biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. More details

QBIO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Q BioMed Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Q BioMed
Historical stock prices
Current Share PriceUS$0.0001
52 Week HighUS$0.041
52 Week LowUS$0.000001
Beta0
11 Month Change9,900.00%
3 Month Change9,900.00%
1 Year Change-83.33%
33 Year Change-99.98%
5 Year Change-99.99%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Shareholder Returns

QBIOUS BiotechsUS Market
7D0%2.4%0.5%
1Y-83.3%15.6%30.7%

Return vs Industry: QBIO underperformed the US Biotechs industry which returned 18.8% over the past year.

Return vs Market: QBIO underperformed the US Market which returned 32.3% over the past year.

Price Volatility

Is QBIO's price volatile compared to industry and market?
QBIO volatility
QBIO Average Weekly Movement6,285.1%
Biotechs Industry Average Movement9.9%
Market Average Movement6.3%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Stable Share Price: QBIO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: QBIO's weekly volatility has decreased from 20792% to 6285% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013n/aDenis Corinwww.qbiomed.com

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer.

Q BioMed Inc. Fundamentals Summary

How do Q BioMed's earnings and revenue compare to its market cap?
QBIO fundamental statistics
Market capUS$14.51k
Earnings (TTM)-US$1.91m
Revenue (TTM)US$209.29k

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
QBIO income statement (TTM)
RevenueUS$209.29k
Cost of RevenueUS$221.90k
Gross Profit-US$12.60k
Other ExpensesUS$1.90m
Earnings-US$1.91m

Last Reported Earnings

Feb 28, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did QBIO perform over the long term?

See historical performance and comparison